EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access · CC BY 4.0

Structured Personalized Oxygen and Supportive Therapies for Dyspnea in Oncology (SPOT-ON): A personalized randomized clinical trial protocol

David Hui iD, Min Ji Kim, Saji Thomas, Gautam Sachdev, Sanjay Shete iD, Nisha Rathi, Nicole Hensch, Vera De La Cruz, Amy Ontai iD, Donald A Mahler, Jie Li, Eduardo Bruera

PLOS One · 2025

DOI: 10.1371/journal.pone.0336691 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS One, 2025. Verfasst von David Hui und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States o…. Hauptthemen laut MEDLINE: Dyspnea, Neoplasms, Oxygen Inhalation Therapy, Precision Medicine. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, Dallas Fort Worth Living Legend Professorship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Low-flow supplemental oxygen (LFSO), high-flow nasal cannula (HFNC), and non-invasive ventilation (NIV) are often used for palliation of dyspnea in hospitalized patients. However, it is unclear how patients prefer to use these modalities and how they can be personalized for optimal dyspnea relief. The objective of this randomized clinical trial is to compare the effect of a personalized respiratory therapist (RT)-led intervention, termed SPOT-ON, and enhanced usual care on dyspnea intensity in both hypoxemic and non-hypoxemic hospitalized patients with cancer.

Methods

In this two-arm, parallel group, partially blinded, waitlist-controlled randomized clinical trial, hospitalized patients with advanced cancer and at least moderate dyspnea intensity at rest (numeric rating scale [NRS] ≥4/10) will be randomized 1:1 to receive SPOT-ON immediately or after a 72-hour waiting period. The SPOT-ON intervention consists of a time-limited trial of LFSO, HFNC, and NIV for 10 minutes each, followed by personalized deployment of these modalities to tailor device settings and timing and duration of use based on patient preference over 72 hours. The waitlist control group will receive structured dyspnea education after enrollment and usual care. The primary outcome will be change in dyspnea NRS intensity from baseline to 24 hours. Secondary outcomes include dyspnea unpleasantness, vital signs, symptom burden, health-related quality of life, adverse events, pattern of device use, and hospital outcomes. We calculated that 150 patients (75 hypoxemic and 75 non-hypoxemic) will provide 80% power to detect a 1.2-point difference between groups with α = 0.025, assuming a standard deviation of 1.5 and 20% attrition.

Discussion

Successful completion of this clinical trial could inform the use of oxygen and supportive modalities to reduce dyspnea. This novel personalized clinical trial methodology involving time-limited trials to tailor therapy based on patient preferences may inform the design of future supportive care clinical trials.

Trial registration

Clinicaltrials.gov NCT06336642

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DyspneaNeoplasmsOxygen Inhalation TherapyPrecision MedicineOxygenHumansFemaleMaleNoninvasive VentilationQuality of LifePalliative CareMiddle AgedRandomized Controlled Trials as Topic

Substanzen

Oxygen

Autor:innen und Institutionen

  • Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
  • Center for Goal Concordant Care Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Critical Care Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
  • Department of Medicine, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, United States of America.

ORCID-Profile: David Hui, Sanjay Shete, Amy Ontai

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • Dallas Fort Worth Living Legend Professorship
  • NCI Cancer Center Support Grant

Zitieren

APA

Hui, D., Kim, M. J., Thomas, S., Sachdev, G., Shete, S., Rathi, N., Hensch, N., De La Cruz, V., Ontai, A., Mahler, D. A., Li, J., & Bruera, E. (2025). Structured Personalized Oxygen and Supportive Therapies for Dyspnea in Oncology (SPOT-ON): A personalized randomized clinical trial protocol. PLOS One. https://doi.org/10.1371/journal.pone.0336691

Vancouver

Hui D, Kim MJ, Thomas S, Sachdev G, Shete S, Rathi N, et al. Structured Personalized Oxygen and Supportive Therapies for Dyspnea in Oncology (SPOT-ON): A personalized randomized clinical trial protocol. PLOS One. 2025. doi:10.1371/journal.pone.0336691

BibTeX
@article{Hui2025,
  author = {Hui, David and Kim, Min Ji and Thomas, Saji and Sachdev, Gautam and Shete, Sanjay and Rathi, Nisha and Hensch, Nicole and De La Cruz, Vera and Ontai, Amy and Mahler, Donald A and Li, Jie and Bruera, Eduardo},
  title = {Structured Personalized Oxygen and Supportive Therapies for Dyspnea in Oncology (SPOT-ON): A personalized randomized clinical trial protocol},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0336691}
}
Kostenlos starten →